

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM820457

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CADENCE BANK, a Mississippi bank and successor by merger to Cadence Bank, N.A., a national banking association, as agent		06/28/2023	bank: MISSISSIPPI
RECEIVING PARTY DATA			
Name:	ENTERIS BIOPHARMA, INC.		
Street Address:	5956 Sherry Lane, Suite 650		
City:	Dallas		
State/Country:	TEXAS		
Postal Code:	75225		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 7			
Property Type	Number	Word Mark	
Serial Number:	87851495	TOBRATE	
Registration Number:	5330032	OVAREST	
Registration Number:	4585895	INTELLIGENT SOLUTIONS FOR ORAL DRUG DELI	
Registration Number:	4585894	ENTERIS BIOPHARMA, INTELLIGENT SOLUTIONS	
Registration Number:	3974071	PEPTELLIGENCE	
Registration Number:	2457466	FORTICAL	
Registration Number:	1917114	FORTICAL	
CORRESPONDENCE DATA			
Fax Number:	4045228409		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4044205527		
Email:	rjk@phrd.com		
Correspondent Name:	Rhonda J. Kenyeri, Paralegal		
Address Line 1:	303 Peachtree Street, Suite 3600		
Address Line 4:	Atlanta, GEORGIA 30308		

OP \$190.00 87851495

NAME OF SUBMITTER:	Kathleen O. Currey
SIGNATURE:	/KOC/
DATE SIGNED:	06/28/2023
Total Attachments: 3 source=02. Release of Security Interest in Trademarks (SWK Holdings)#page1.tif source=02. Release of Security Interest in Trademarks (SWK Holdings)#page2.tif source=02. Release of Security Interest in Trademarks (SWK Holdings)#page3.tif	

RELEASE OF SECURITY INTEREST IN TRADEMARKS

June 28, 2023

FOR VALUE RECEIVED, the undersigned, **CADENCE BANK**, a Mississippi bank and successor by merger to Cadence Bank, N.A., a national banking association, as agent for various financial institutions (together with its successors and assigns, "Agent"), does hereby release, relinquish, terminate and cancel any and all liens and security interests granted to Agent by the Company (as defined below), in and to the trademarks listed on Schedule A attached hereto (collectively, the "Trademark Collateral"), arising under that certain Trademark Security Agreement dated August 26, 2019, by and between **ENTERIS BIOPHARMA, INC.**, a Delaware corporation (the "Company"), and Agent, recorded with the United States Patent and Trademark Office on August 27, 2019, at Reel 6730, Frame 0782 (the "Trademark Agreement"). This Release of Security Interest in Trademarks (this "Release") may be filed with the United States Patent and Trademark Office to evidence Agent's release of the security interest against such trademarks.

This Release is intended to operate as a release of all liens and security interests in the trademarks listed on Schedule A attached hereto, conveyed by the Company to Agent pursuant to the terms of the Trademark Agreement, without any representation, warranty or undertaking by, or recourse to, Agent. If and to the extent Agent has acquired any right, title or interest in and to any of the Trademark Collateral pursuant to the terms of the Trademark Agreement, Agent hereby reassigns and transfers such right, title and interest to the Company, together with the goodwill of the Company's business connected with and symbolized by the Trademark Collateral, without any representation, warranty or undertaking by, or recourse to, Agent.

[Remainder of page intentionally left blank; signature appears on the following page.]

IN WITNESS WHEREOF, Agent has caused this Release to be signed and sealed by its duly authorized officer as of the date first written above.

CADENCE BANK, successor by merger to
Cadence Bank, N.A., as Agent

By: Kenneth B. Butler
Name: Kenneth B. Butler
Title: Senior Vice President

SCHEDULE A

Trademarks and Trademark Applications

<u>Mark</u>	<u>Application No. Registration No.</u>	<u>Application Date Registration Date</u>	<u>Owner</u>	<u>Country</u>
TOBRATE	87/851,495 N/A	3/27/2018 N/A	Enteris BioPharma Inc.	US
OVAREST	86/400,353 5,330,032	9/19/2014 11/7/2017	Enteris BioPharma Inc.	US
INTELLIG ENT SOLUTION S FOR ORAL DRUG DELIVERY *	86/027,630 4,585,895	8/2/2013 8/12/2014	Enteris BioPharma Inc.	US
ENTERIS BIOPHAR MA, INTELLIG ENT SOLUTION S FOR ORAL DRUG DELIVERY *	86/027,541 4,585,894	8/2/2013 8/12/2014	Enteris BioPharma Inc.	US
PEPELLI GENCE	85/153,772 3,974,071	10/15/2010 6/7/2011	Enteris BioPharma Inc.	US
FORTICAL **	74/608,739 2,457,466	12/8/1994 6/5/2001	Enteris BioPharma Inc.	US
FORTICAL **	74/485,072 1,917,114	2/1/1994 9/5/1995	Enteris BioPharma Inc.	US
FORTICAL **	636214 636214	7/28/1994 8/25/1995	Enteris BioPharma Inc.	AU
FORTICAL **	8740143 8740143	10/14/2010 10/21/2011	Enteris BioPharma Inc.	CN